The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses

Laboratory Investigation

Volumn 87, Issue 9, 2007, Pages 858-870

  Bellini, Alberto ^a   Mattoli, Sabrina ^a  

^a Avail Biomedical Research Institute   (Switzerland)

Author keywords

Asthma; Atherosclerosis; Fibrocytes; Myofibroblasts; Tissue repair; Tumor

Indexed keywords

CELL MARKER;

AIRWAY; ASTHMA; ATHEROSCLEROSIS; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MATURATION; CELL POPULATION; CELL STIMULATION; CHRONIC PANCREATITIS; CYSTITIS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; HEMATOPOIESIS; HUMAN; HYPERTROPHIC SCAR; HYPOXEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KELOID; KIDNEY CYST; LUNG DISEASE; LUNG FIBROSIS; MESENCHYME CELL; MONOCYTE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; TISSUE INJURY; WOUND HEALING;

ANIMALS; ASTHMA; ATHEROSCLEROSIS; CELL DIFFERENTIATION; FIBROSIS; HUMANS; MESENCHYMAL STEM CELLS; WOUND HEALING;

EID: 34547960749     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700654     Document Type: Short Survey

References (128)

1. Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994;1:71-81.
2. Chesney J, Metz C, Stavitsky AB, et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998;160:419-425.
3. Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001;166:7556-7562.
4. Yang L, Scott PG, Giuffre J, et al. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest 2002;82:1183-1192.
5. Pilling D, Buckley CD, Salmon M, et al. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003;171:5537-5546.
6. Mori L, Bellini A, Stacey MA, et al. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 2005;304:81-90.
7. Ebihara Y, Masuya M, Larue AC, et al. Hematopoietic origins of fibroblasts: II. In vitro studies of fibroblasts, CFU-F and fibrocytes. Exp Hematol 2006;34:219-229.
8. Kisseleva T, Uchinami H, Feirt N, et al. Bone-marrow derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006;45:429-438.
9. Haudek SB, Xia Y, Huebener P, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci USA 2006;103:18284-18289.
10. Pilling D, Tucker NM, Gomer RH. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 2006;79:1242-1251.
11. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171:380-389.
12. Yang L, Scott PG, Dodd C, et al. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005;13:2215-2224.
13. + fibrocytes in neoplastic and inflammatory pancreatic lesions. Virchows Arch 2002;440:128-133.
14. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003;25:358.
15. Nihlberg K, Larsen K, Hultgardh-Nilsson A, et al. Tissue fibrocytes in patients with mild asthma: a possible link to thickness of reticular basement membrane? Respir Res 2006;7:50 (doi:10.1186/1465-9921-7-50).
16. Kaur D, Saunders R, Berger P, et al. Airway smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth muscle migration in asthma. Am J Respir Crit Care Med 2006;174:1179-1188.
17. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-446.
18. Moore BB, Kolodsick JE, Thannickal VJ, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005;166:675-684.
19. Mattoli S. Tissue repair in asthma: the origin of airway subepithelial fibroblasts and myofibroblasts. In: Chaponnier C, Desmoulière A, Gabbiani G (eds). Tissue Repair, Contraction and the Myofibroblast, Chapter 4. Landes Bioscience and Springer Science, Business Media: Georgetown, TX, 2006, pp 40-46.
20. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006;168:659-669.
21. Moore BB, Murray L, Das A, et al. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006;35:175-181.
22. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006;103:14098-14103.
23. Varcoe RL, Mikhail M, Guiffre AK, et al. The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost 2006;4:1125-1133.
24. + fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Wirchows Archiv 2007;450:179-185.
25. Barth PJ, Ramaswamy A, Moll R. CD34(+) fibrocytes in normal cervical stroma, cervical intraepithelial neoplasia III, and invasive squamous cell carcinoma of the cervix uteri. Virchows Arch 2002;441:564-568.
26. + fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ and benign breast lesions. Virchows Arch 2002;440:298-303.
27. Ramaswamy A, Moll R, Barth PJ. CD34(+) fibrocytes in tubular carcinomas and radial scars of the breast. Virchows Arch 2003;443:536-540.
28. Chauhan H, Abraham A, Phillips JRA, et al. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast cancer. J Clin Pathol 2003;56:271-276.
29. Kuroda N, Toi M, Nakayama H, et al. The distribution and role of myofibroblasts and CD34-positive stromal cells in normal pancreas and various pancreatic lesions. Histol Histopathol 2004;19:59-67.
30. + fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch 2004;444:231-234.
31. Yazhou C, Wenlv S, Weidong Z, et al. Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. Tumour Biol 2004;25:290-295.
32. Kojc N, Zidar N, Vodopivec B, et al. Expression of CD34, alpha-smooth muscle actin, and transforming growth factor beta1 in squamous intraepithelial lesions and squamous cell carcinoma of the larynx and hypopharynx. Human Pathol 2005;36:16-21.
33. Hong KM, Burdick MD, Phillips RJ, et al. Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J 2005;19:2029-2031.
34. Chesney J, Bacher M, Bender A, et al. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naïve T cells in situ. Proc Natl Acad Sci USA 1997;94:6307-6312.
35. Balmelli C, Ruggli N, McCullough K, et al. Fibrocytes are potent stimulators of anti-virus cytotoxic T cells. J Leukoc Biol 2005;77:923-933.
36. Wang J, Jiao H, Stewart T, et al. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen 2007;15:113-121.
37. Hartlapp I, Abe R, Saeed RW, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001;15:2215-2224.
38. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature Rev Immunol 2005;5:953-964.
39. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006;211:609-618.
40. Sunderkotter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004;172:4410-4417.
41. Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc Natl Acad Sci USA 2003;100:2426-2431.
42. + monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003;74:833-845.
43. Kim CH, Pelus LM, White JR, et al. Macrophage-inflammatory protein-3β/EB11-ligand chemokine/CKβ-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells. J Immunol 1998;161:2580-2585.
44. Kim CH, Broxmeyer HE. SLC/exodus/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs suppression of progenitor proliferation. J Leukoc Biol 1999;66:455-461.
45. He Q, Wan C, Li G. Concise review: multipotent mesenchymal stromal cells in blood. Stem Cells 2007;25:69-77.
46. Hennrick KT, Keeton AG, Nanua S, et al. Lung cells from neonates show a mesenchymal stem cell phenotype. Am J Respir Crit Care Med 2007;175:1158-1164.
47. med,low phenotype. Br J Haematol 2003;122:506-517.
48. Pilling D, Gomer RH. Regulatory pathways for fibrocyte differentiation. Chapter 3. In: Bucala R (ed). Fibrocytes: New Insights Into Tissue Repair and Systemic Fibroses. World Scientific Publishing Co. Pte. Ltd.: Singapore, 2007, pp 37-60.
49. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-870.
50. Ishii G, Sangai T, Sugiyama K, et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 2005;23:699-706.
51. Ishida Y, Kimura A, Kondo T, et al. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am J Pathol 2007;170:843-854.
52. Tredget EE, Nedelec B, Scott PG, et al. Hypertrophic scars, keloid, and contractures. The cellular and molecular basis for therapy. Surg Clin N Am 1997;77:701-730.
53. Scott PG, Ghahary A, Tredget EE. Molecular and cellular aspects of fibrosis following thermal injury. Hand Clin 2000;16:271-287.
54. Ehrlich HP, Desmouliere A, Diegelmann RF, et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol 1994;145:105-113.
55. Santucci M, Borgognoni L, Reali UM, et al. Keloids and hypertrophic scars of Caucasians show distinctive morphologic and immunophenotypic profiles. Virchows Arch 2001;438:457-463.
56. Ghahary A, Shen YJ, Scott PG, et al. Enhanced expression of mRNA for transforming growth factor-β, type I and III procollagen in human post-burn hypertrophic scar tissues. J Lab Clin Med 1993;122:465-473.
57. Aiba S, Tagami H. Inverse correlation between CD34 expression and proline-4-hydroxylase immunoreactivity on spindle cells noted in hypertrophic scars and keloids. J Cutan Pathol 1997;24:65-69.
58. Hartert TV, Peebles Jr RS. Epidemiology of asthma: the year in review. Curr Opin Pulm Med 2000;6:4-9.
59. Kiley J, Smith R, Noel P. Asthma phenotypes. Curr Opin Pulm Med 2007;13:19-23.
60. Laitinen LA, Heino M, Laitinen A, et al. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985;131:599-606.
61. Shahana S, Bjornsson E, Ludviksdottir D, et al. Ultrastructure of bronchial biopsies from patients with allergic and non-allergic asthma. Respir Med 2005;99:429-443.
62. Mattoli S. Allergen-induced generation of mediators in the mucosa. Environ Health Perspect 2001;109(Suppl 4):553-557.
63. Marini M, Avoni E, Hollemborg J, et al. Cytokine mRNA profile and cell activation in bronchoalveolar lavage fluid from nonatopic patients with symptomatic asthma. Chest 1992;102:661-669.
64. Ackerman V, Marini M, Vittori E, et al. Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients: relationship to atopic status, symptoms, and level of airway hyperresponsiveness. Chest 1994;105:687-696.
65. Elias JA, Zhu Z, Chupp G, et al. Airway remodeling in asthma. J Clin Invest 1999;104:1001-1006.
66. Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airway inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-1745.
67. Brewster CEP, Howarth PH, Djukanovic R, et al. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990;3:507-511.
68. Stewart AG, Tomlinson PR, Wilson J. Airway wall remodeling in asthma: a novel target for the development of anti-inflammatory drugs. Trend Pharmacol Sci 1993;14:275-279.
69. Gabbrielli S, Di Lollo S, Stanflin N, et al. Myofibroblasts and elastic and collagen fiber hyperplasia in the bronchial mucosa: a possible basis for the progressive irreversibility of airflow obstruction in asthma. Pathologica 1994;86:157-160.
70. Fish JE, Peters SP. Airway remodeling and persistent airway obstruction in asthma. J Allergy Clin Immunol 1999;104:509-516.
71. Rose Jr CE, Sung SJ, Fu SM. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation 2003;10:273-288.
72. Mattoli S, Schmidt M. Role in asthmatic lung disease. Chapter 6. In: Bucala R (ed). Fibrocytes: New Insights Into Tissue Repair and Systemic Fibroses. World Scientific Publishing Co. Pte. Ltd.: Singapore, 2007, pp 105-123.
73. O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987;136:740-751.
74. Lemanske RF, Kaliner MA. Late phase allergic reactions. In: Middleton Jr E, Reed CE, Ellis EF, Adkinson NF, Yuninger JW, Busse WW (eds). Allergy: Principles and Practice, 4th edn. Mosby Yearbook: St Louis, 1993, pp 320-361.
75. Gizycki MJ, Adelroth E, Rogers A, et al. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol 1997;16:664-673.
76. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
77. Gross TJ, Hunninghake GW. Idiopatic pulmonary fibrosis. N Engl J Med 2001;345:517-525.
78. Mason RJ, Schwarz MI, Hunninghake GW, et al. NHLBI workshop summary, pharmacological therapy for idiopatic pulmonary fibrosis. Past, present and future. Am J Respir Crit Care Med 1999;160:1771-1777.
79. Perez A, Rogers RM, Dauber JH. The prognosis of idiopatic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29(Suppl 3):S19-S26.
80. Katzenstein AA, Myers JL. Idiopatic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-1315.
81. King Jr TE, Schwarz MI, Brown K, et al. Idiopatic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-1032.
82. Choi ES, Pierce EM, Jakubzick C, et al. Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopatic interstitial pneumonia. J Clin Pathol 2006;59:28-39.
83. Mehrad B, Burdick MD, Zisman DA, et al. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007;353:104-108.
84. Pierce EM, Carpenter K, Jakubzick C, et al. Idiopatic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J 2007;29:1082-1093.
85. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18:614-617.
86. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
87. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
88. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-393.
89. Ortonne N, Lipsker D, Chantrel F, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenetic hypothesis. Br J Dermatol 2004;150:1050-1052.
90. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum 2004;50:2660-2666.
91. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of twelve cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238-249.
92. Spencer A, Wilson S, Batchelor J, et al. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997;25:245-255.
93. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origin of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004;16:733-738.
94. Sakkas LI. New development in the pathogenesis of systemic sclerosis. Autoimmunity 2005;38:113-116.
95. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:134-144.
96. Kowal-Bielecka O. Targeting vascular disease in systemic sclerosis. Endocr Metab Immune Disord Drug Targets 2006;6:401-407.
97. Fleischmajer R, Perlish JS. Capillary alterations in scleroderma. J Am Acad Dermatol 1980;2:161-170.
98. Kraling BM, Maul GG, Jimenez SA. Mononuclear cell infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995;63:48-56.
99. Kirk TZ, Mark ME, Chua CC, et al. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995;270:3423-3428.
100. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-165.
101. Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-2678.
102. Yamamoto T, Eckes B, Hartmann K, et al. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001;26:133-139.
103. Odoux C, Crestani B, Lebrun G, et al. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med 1997;156:1429-1435.
104. Kinsella MB, Smith EA, Miller KS, et al. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum 1989;32:577-583.
105. Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772-3782.
106. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNFα. J Exp Med 1996;184:695-706.
107. + spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol 1994;130:593-597.
108. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-2234.
109. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
110. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transducer an atheroprotective force. Arterioscler Thromb Vasc Biol 1998;18:677-685.
111. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995;57:791-804.
112. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1994;14:840-856.
113. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995;15:1512-1531.
114. Andreeva ER, Pugach IM, Orekhov AN. Collagen-synthesizing cells in initial and advanced atherosclerosis lesions of human aorta. Atherosclerosis 1997;130:133-142.
115. Pasterkamp G, de Kleijn DP, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res 2000;45:843-852.
116. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-1339.
117. Fletcher JP, Guiffre A, Medbury H. Fibrocytes in atherosclerosis: VS022. ANZ Journal of Surgery 2005;75(Suppl):A119.
118. Medbury H. Role of fibrocytes in atherogenesis. Chapter 10. In: Bucala R (ed). Fibrocytes: New Insights Into Tissue Repair and Systemic Fibroses. World Scientific Publishing Co. Pte. Ltd.: Singapore, 2007, pp 175-194.
119. Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis 1997;135:19-27.
120. high monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007;117:195-205.
121. Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004;44:1812-1818.
122. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005;112:1113-1120.
123. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-381.
124. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002;22:975-982.
125. Ishii G, Sangai T, Oda T, et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 2003;309:232-240.
126. Direkze NC, Hodivala-Dilke K, Jeffery R, et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004;64:8492-8495.
127. Bridle KR, Crawford DH, Powell LW, et al. Role of myofibroblasts in tumour encapsulation of hepatocellular carcinoma in haemochromatosis. Liver 2001;21:96-104.
128. Olson T, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regulatory Integrative Comp Physiol 2002;283:R7-R28.